European Commission commits €100bn for research and innovation

The European Commission has proposed that the next long-term EU budget (2021-2027) includes €100 billion ($117.55 billion) for research and innovation, in what it calls the most ambitious such programme yet.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

EC reveals plans for unitary SPC, compulsory licences

8 February 2022 The European Commission will unveil plans to make supplementary protection certificates more accessible and efficient for pharmaceutical companies to register and enforce by the end of March.

Big Pharma

European Commission proposes SPC waiver to boost generics

29 May 2018 The European Commission has proposed a change in IP rules to allow pharmaceutical companies to produce generic drugs for export to non-EU countries that don’t have patent protection.

Big Pharma

European Commission targets alleged ‘pay-for-delay’ with pharma fines

20 June 2013 The European Commission’s competition directorate has levied fines totalling €146 million ($195 million) against originator pharmaceutical company Lundbeck and several producers of generics drugs.

More on this story

Europe

EC reveals plans for unitary SPC, compulsory licences

Big Pharma

European Commission proposes SPC waiver to boost generics

29 May 2018 The European Commission has proposed a change in IP rules to allow pharmaceutical companies to produce generic drugs for export to non-EU countries that don’t have patent protection.

Big Pharma

European Commission targets alleged ‘pay-for-delay’ with pharma fines

More on this story

Europe

EC reveals plans for unitary SPC, compulsory licences

Big Pharma

European Commission proposes SPC waiver to boost generics

29 May 2018 The European Commission has proposed a change in IP rules to allow pharmaceutical companies to produce generic drugs for export to non-EU countries that don’t have patent protection.

Big Pharma

European Commission targets alleged ‘pay-for-delay’ with pharma fines